ProMetic BioSciences Postpones IPO as Business Outlook Brightens | GenomeWeb
NEW YORK (GenomeWeb News) — Prometic Life Sciences today said an improved financial and competitive landscape has caused it to postpone plans to file an initial public offering for its ProMetic BioSciences subsidiary, a maker of synthetic proteins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.